Another phase I/II study evaluated ASKB589 combined with chemotherapy (CAPOX) and sintilimab (a PD-1 inhibitor) as first-line treatment for locally advanced, relapsed, and metastatic CLDN18.2-positive GC/GEJC, regardless of PD-L1 status (NCT05632939). This evidence concerns the gene CLDN18 and gastric cancer.